Collection 4 (Sep 2023 - Aug 2024) Articles

Articles
Dyslipidaemia as a target for atherosclerotic cardiovascular disease prevention in children with type 1 diabetes: lessons learned from familial hypercholesterolaemia
Corpeleijn WE, de Waal WJ, Schipper HS, et al.
Journal:
Diabetologia

First published: November 30, 2023 DOI: 10.1007/s00125-023-06041-z
View
- Share
Articles
Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias’ treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network meta-analysis
Pamporis K, Karakasis P, Simantiris S, et al.
Journal:
Clin Investig Arterioscler

First published: November 30, 2023 DOI: 10.1016/j.arteri.2023.11.003
View
- Share
Articles
Increased FH-Risk-Score and Diabetes Are Cardiovascular Risk Equivalents in Heterozygous Familial Hypercholesterolemia
Paquette M, Cariou B, Bernard S, et al.
Journal:
Arterioscler Thromb Vasc Biol

First published: November 30, 2023 DOI: 10.1161/ATVBAHA.123.319957
View
- Share
Articles
Determinants of Progression and Regression of Subclinical Atherosclerosis Over 6 Years
Mendieta G, Pocock S, Mass V, et al.
Journal:
J Am Coll Cardiol

First published: November 28, 2023 DOI: 10.1016/j.jacc.2023.09.814
View
- Share
Articles
Novel Imaging Approaches to Cardiac Manifestations of Systemic Inflammatory Diseases: JACC Scientific Statement
Weber BN, Paik JJ, Aghayev A, et al.
Journal:
J Am Coll Cardiol

First published: November 28, 2023 DOI: 10.1016/j.jacc.2023.09.819
View
- Share
Articles
Primary Prevention of Subclinical Atherosclerosis in Young Adults: JACC Review Topic of the Week
Devesa A, Ibanez B, Malick WA, et al.
Journal:
J Am Coll Cardiol

First published: November 28, 2023 DOI: 10.1016/j.jacc.2023.09.817
View
- Share
Articles
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study
Moon JS, Park IR, Kim SS, et al.
Journal:
Diabetes Metab J

First published: November 24, 2023 DOI: 10.4093/dmj.2023.0171
View
- Share
Articles
Bempedoic acid – how will it shape the future lipid-lowering landscape? Mode of action, evidence, and clinical use
Drexel H, Mader A
Journal:
Cardiology

First published: November 21, 2023 DOI: 10.1159/000535372
View
- Share
Articles
Cascade testing of children and adolescents for elevated Lp(a) in pedigrees with familial Hypercholesterolaemia
Loh WJ, Pang J, Chakraborty A, et al.
Journal:
J Clin Lipidol

First published: November 17, 2023 DOI: 10.1016/j.jacl.2023.11.007
View
- Share
Articles
Comparison of virtual vs face-to-face medical nutrition therapy in patients with hyperlipidemia
Zoulek S, Shriver J, Kaur N, et al.
Journal:
J Clin Lipidol

First published: November 16, 2023 DOI: 10.1016/j.jacl.2023.11.005
View
- Share
Articles
Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial
Nissen SE, Linnebjerg H, Shen X, et al.
Journal:
JAMA

First published: November 12, 2023 DOI: 10.1001/jama.2023.21835
View
- Share
Articles
Development and Validation of the American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations
Khan SS, Matsushita K, Sang Y, et al.
Journal:
Circulation

First published: November 10, 2023 DOI: 10.1161/CIRCULATIONAHA.123.067626
View
- Share

1 … 8 9 10 11 12

Collection 4 (Sep 2023 - Aug 2024) Articles

Articles

Dyslipidaemia as a target for atherosclerotic cardiovascular disease prevention in children with type 1 diabetes: lessons learned from familial hypercholesterolaemia

Corpeleijn WE, de Waal WJ, Schipper HS, et al.

Articles

Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias’ treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network meta-analysis

Pamporis K, Karakasis P, Simantiris S, et al.

Articles

Increased FH-Risk-Score and Diabetes Are Cardiovascular Risk Equivalents in Heterozygous Familial Hypercholesterolemia

Paquette M, Cariou B, Bernard S, et al.

Articles

Determinants of Progression and Regression of Subclinical Atherosclerosis Over 6 Years

Mendieta G, Pocock S, Mass V, et al.

Articles

Novel Imaging Approaches to Cardiac Manifestations of Systemic Inflammatory Diseases: JACC Scientific Statement

Weber BN, Paik JJ, Aghayev A, et al.

Articles

Primary Prevention of Subclinical Atherosclerosis in Young Adults: JACC Review Topic of the Week

Devesa A, Ibanez B, Malick WA, et al.

Articles

The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study

Moon JS, Park IR, Kim SS, et al.

Articles

Bempedoic acid – how will it shape the future lipid-lowering landscape? Mode of action, evidence, and clinical use

Drexel H, Mader A

Articles

Cascade testing of children and adolescents for elevated Lp(a) in pedigrees with familial Hypercholesterolaemia

Loh WJ, Pang J, Chakraborty A, et al.

Articles

Comparison of virtual vs face-to-face medical nutrition therapy in patients with hyperlipidemia

Zoulek S, Shriver J, Kaur N, et al.

Articles

Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial

Nissen SE, Linnebjerg H, Shen X, et al.

Articles

Development and Validation of the American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations

Khan SS, Matsushita K, Sang Y, et al.

Articles

Dyslipidaemia as a target for atherosclerotic cardiovascular disease prevention in children with type 1 diabetes: lessons learned from familial hypercholesterolaemia

Corpeleijn WE, de Waal WJ, Schipper HS, et al.

Share

Articles

Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias’ treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network meta-analysis

Pamporis K, Karakasis P, Simantiris S, et al.

Share

Articles

Increased FH-Risk-Score and Diabetes Are Cardiovascular Risk Equivalents in Heterozygous Familial Hypercholesterolemia

Paquette M, Cariou B, Bernard S, et al.

Share

Articles

Determinants of Progression and Regression of Subclinical Atherosclerosis Over 6 Years

Mendieta G, Pocock S, Mass V, et al.

Share

Articles

Novel Imaging Approaches to Cardiac Manifestations of Systemic Inflammatory Diseases: JACC Scientific Statement

Weber BN, Paik JJ, Aghayev A, et al.

Share

Articles

Primary Prevention of Subclinical Atherosclerosis in Young Adults: JACC Review Topic of the Week

Devesa A, Ibanez B, Malick WA, et al.

Share

Articles

The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study

Moon JS, Park IR, Kim SS, et al.

Share

Articles

Bempedoic acid – how will it shape the future lipid-lowering landscape? Mode of action, evidence, and clinical use

Drexel H, Mader A

Share

Articles

Cascade testing of children and adolescents for elevated Lp(a) in pedigrees with familial Hypercholesterolaemia

Loh WJ, Pang J, Chakraborty A, et al.

Share

Articles

Comparison of virtual vs face-to-face medical nutrition therapy in patients with hyperlipidemia

Zoulek S, Shriver J, Kaur N, et al.

Share

Articles

Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial

Nissen SE, Linnebjerg H, Shen X, et al.

Share

Articles

Development and Validation of the American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations

Khan SS, Matsushita K, Sang Y, et al.

Share